Non-hazardous viral inactivation medium for Covid-19 available in Europe
Breakthrough formulation helps reduce the risk of exposure using a non-hazardous formulation and leakproof format during transport and processing
Breakthrough formulation helps reduce the risk of exposure using a non-hazardous formulation and leakproof format during transport and processing
The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts
SAATH is a ‘One AXA’ public health initiative between AXA France Vie, AXA GO Business Operations, and AXA XL
The Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (UZH) and Insilico Medicine will be working together to identify, rank, and annotate novel drug targets to identify potential therapeutics for cystinosis
Paxlovid is the first oral therapy specifically designed to combat Covid-19 to be evaluated in a pediatric clinical study
It has blended 36 important ingredients for a woman’s health, which has a mix of natural extracts, amino acids, multivitamins and minerals
Using Orion, pharmaceutical and biotechnology companies, as well as any industrial researcher who wishes to perform electronic structure calculations, can gain access to elastic and flexible computational resources in the Cloud
Price was the key driver for the period
This collaboration has resulted in several high-impact scientific publications describing breakthrough inventions, including the SOMA robotic pill, which has subsequently been licensed exclusively to Novo Nordisk for clinical development
The DCGI has already approved Covovax for restricted use in emergency situations in adults on December 28th 2021
Subscribe To Our Newsletter & Stay Updated